Aspire Biopharma Holdings (ASBP) Free Cash Flow (2021 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Free Cash Flow of -$3.0 million for Q1 2026, down 73.48% year-over-year from -$11.5 million in Q1 2025, and down 227.48% quarter-over-quarter from -$927841.0 in Q4 2025.
Aspire Biopharma Holdings (ASBP) Free Cash Flow (2021 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Free Cash Flow for 6 consecutive years, with -$3.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 73.48% year-over-year to -$3.0 million; the TTM figure through Mar 2026 stood at -$6.2 million (down 240.53% YoY), while the FY2025 annual figure was -$4.9 million, down 1214.54% from the prior year.
- Free Cash Flow slipped to -$3.0 million in Q1 2026 per ASBP's latest filing, from -$927841.0 in the prior quarter.
- Across five years, Free Cash Flow topped out at $479569.0 in Q4 2024 and bottomed at -$3.0 million in Q1 2026.
- Historically, Free Cash Flow has averaged -$605240.5 across 5 years, with a median of -$189951.0 in 2023.
- Annual changes were most pronounced in 2024 — Free Cash Flow jumped 407.16% — and 2025, when it tumbled 1927.43%.
- Aspire Biopharma Holdings' Free Cash Flow stood at -$35870.0 in 2022, then plunged by 335.26% to -$156128.0 in 2023, then surged by 407.16% to $479569.0 in 2024, then tumbled by 293.47% to -$927841.0 in 2025, then plunged by 227.48% to -$3.0 million in 2026.
- Business Quant data shows ASBP's Free Cash Flow at -$3.0 million in Q1 2026, -$927841.0 in Q4 2025, and -$1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 | -2.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.12 Mn |
| Jun 30, 2026 | -2.12 Mn |
| Mar 31, 2026 | -3.04 Mn |
| Mar 31, 2026 | -3.04 Mn |
| Dec 31, 2025 | -927,841.00 |
| Dec 31, 2025 | -927,841.00 |
| Sep 30, 2025 | -1.10 Mn |
| Sep 30, 2025 | -1.10 Mn |
| Jun 30, 2025 | -1.14 Mn |
| Jun 30, 2025 | -1.14 Mn |
| Mar 31, 2025 | -1.75 Mn |
| Mar 31, 2025 | -1.75 Mn |
| Dec 31, 2024 | 479,569.00 |
| Dec 31, 2024 | 479,569.00 |
| Sep 30, 2024 | -495,540.00 |
| Sep 30, 2024 | -495,540.00 |
| Jun 30, 2024 | -56,244.00 |
| Jun 30, 2024 | -56,244.00 |
| Mar 31, 2024 | -192,971.00 |
| Mar 31, 2024 | -192,971.00 |